OSR Health, Inc.
OSRHW- Exchange
- OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001840425
No open-market purchases or sales by OSR Health, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $199.7K in total; no superinvestor holds it.
Other share classesOSRH
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by OSR Health, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for OSR Health, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hwang Kuk Hyoun | President and CEO | 12,699,104Indirect | Feb 19, 2025 | 0 |
| Bellevue Global Life Science Investors LLC | 10% Owner | 2,043,500 | Feb 19, 2025 | 0 |
| Yoo David Jin | Chief Financial Officer | 20,000 | Mar 27, 2023 | 0 |
| Reed Steven | Director | 20,000 | Feb 16, 2023 | 0 |
| Chung In Chul | Director | 20,000 | Feb 16, 2023 | 0 |
| Euh Hosun | Director | 20,000 | Feb 16, 2023 | 0 |
| Park Jin Whan | Director | 20,000 | Feb 16, 2023 | 0 |
| Roberts Rad | Director | 20,000 | Feb 16, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 16, 2023 (view filing) | Feb 14 | 2 days | Bellevue Global Life Science Investors LLC10% Owner | PPurchase | +430.0K | $10.00 | +$4.30M | –430.0K after | DerivativeDuplicate filing |
| Feb 16, 2023 (view filing) | Feb 14 | 2 days | Hwang Kuk HyounChief Executive Officer | PPurchase | +430.0K | $10.00 | +$4.30M | –430.0K after | Derivative |